Navigation Links
Drug-Device Combination Market Worth US$18.54 Billion by 2014
Date:7/28/2009

WILMINGTON, Delaware, July 28 /PRNewswire/ -- According to a new market research report, 'Drug-Device Combination Market (2009 - 2014)', published by MarketsandMarkets (http://www.marketsandmarkets.com), the total drug-device combination market is expected to be worth US$18.54 billion by 2014, out of which the U.S. market will account for nearly 30.9% of the total revenues. The global market is expected to record a CAGR of 11.8% from 2009 to 2014.

Browse 144 market data tables and in-depth TOC on drug-device market. Early buyers will receive 10% customization of reports

http://www.marketsandmarkets.com/Market-Reports/drug-and-device-combinati

on-101.html

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

The drug-device combination market ( http://www.marketsandmarkets.com/ Market-Reports/drug-and-device-combination-101.html ) includes all the products that are a combination of drugs and devices and can be chemically or physically united or co-packaged as separate, cross labeled products. The market is driven by the growing demand for treating only the ; targeted area, increasing incidences of infections associated with regular medical devices, need for faster healing, and overall reduced cost of treatment and accelerated approval process of the drug-device combination products.

(Due to the length of the URL in the above paragraph, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

The drug eluting stents (DES) market is the largest segment and is expected to reach US$8.47 billion by 2014 at a CAGR of 9.3%. The antimicrobial catheter market is estimated to grow to a size of US$1.23 billion in 2014 which presents the highest growth potential with an expected growth rate of 23.4% in 2014. The cardiovascular treatment market is estimated to record revenues of US$9.59 billion in 2014 on account of the fact that cardiovascular diseases are one of the primary causes of death globally.

The European market is the largest geographical segment; and is expected to be worth US$7.25 billion by 2014. Its 11.2% CAGR for 2009 to 2014 is driven by the growing ageing population and the improvements in medical science and biotechnology that enables new product development. The second largest segment is the U.S. with a CAGR of 8.7% for 2009 to 2014. It is expected to reach US$5.73 billion by 2014.

The report is titled 'Drug-Device Combination Market (2009-2014) and was published in July 2009.

Scope of the Report

This report aims to identify the specific segments that offer the highest growth potential in the near future; compares the products in respect to the relative entry barriers and expected new product developments in those segments. The report discusses the segmentation of the global drug-device combination as follows:

1. Drug device combination - products

Antimicrobial catheter, advanced wound care products, bone graft substitutes, antibiotic bone cements, drug eluting stents, photodynamic therapy, closed loop glucose monitor and insulin pump, steroid eluting electrodes and others.

2. Drug device combination - application

Bone treatment, cancer treatment, diabetes treatment, skin care treatment, antimicrobial applications, urological treatment, non cardiovascular treatment, cardiovascular treatment, ophthalmic treatment, others.

3. Drug device combination - technology

Bone graft substitutes- synthetic bone graft substitutes, demineralised bone matrix and bone morphogenic proteins.

Contact our representative to sponsor this report

About MarketsandMarkets

MarketsandMarkets is a research and consulting firm that publishes 120 market research (http://www.marketsandmarkets.com) reports per year. Each strategically analyzed report contains 250 pages of valuable market data, including more than 100 market data Summary tables and in-depth, five-level segmentation for each of the products, services, applications, technologies, ingredients and stakeholders categories. Our reports also analyze about 200 patents, over 50 companies and micro markets that are mutually exclusive and collectively exhaustive. Browse all our 120 titles at http://www.marketsandmarkets.com.

    Contact:
    Ms. Sunita
    108, West 13th Street,
    Wilmington
    DE, 19801
    County of New Castle
    Tel: +1-888-989-8004
    Email: sales@marketsandmarkets.com



'/>"/>
SOURCE MarketsandMarkets
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
2. 96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy
3. Combination Therapy Best for Aggressive Prostate Cancer
4. Particle Sciences Further Expands Combination Product Development Capabilities
5. QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R) combination therapy
6. Abbotts TRILIPIX(R) (Fenofibric Acid) in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet American Diabetes Association Lipid Targets
7. QLT announces positive results from the evaluation of Visudyne(R) combination therapy
8. 2-drug combination appears safe and active in metastatic kidney cancer
9. New treatment combination proves safe for head and neck cancer patients
10. Study shows drug combination improves outcome for advanced non-small cell lung cancer
11. Chemotherapy combination outcomes differ for aged, younger colon cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & Associates, a locally ... business owners in North Central West Virginia, is embarking on a cooperative charity ... residents in the region. , The Stepping Stones organization offers a series of ...
(Date:6/22/2017)... ... 2017 , ... Plastic Surgery Associates is proud to report that founding surgeon, ... research and information firm, Castle Connolly, releases their list of the most notable and ... 3rd time that Dr. Canales has been recognized by Castle Connolly. , ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... from the American Heart Association (AHA) to launch a Rheumatic Heart Disease Center, ... prevention and diagnosis of rheumatic heart disease (RHD) in high-risk, financially disadvantaged countries ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... announced today that it has received certification for ANSI/ASIS PSC.1-2012. The company’s work ... in environments where the rule of law has been degraded. The PSC.1 standard ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, ... a Nashville-based private equity firm, has invested $3.35 million in the company. ... and Claritas Capital offers the smart money, speed to market and accountability we ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... 2017  Eli Lilly and Company (NYSE: ... the Phase 3 MONARCH 2 study showed that ... in combination with fulvestrant, significantly improved progression-free survival ... women with hormone-receptor-positive (HR+), human epidermal growth factor ... relapsed or progressed after endocrine therapy (median PFS, ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology: